Over $500 Million Recovered

Free Confidential Case Review, No Fees Unless We Recover For You

(212) 779-0057
Blood coagulant Eliquis is under attack in defective drug lawsuit

If you've been injured in an accident or on the job, the attorneys of Hach & Rose, LLP have the knowledge, skills, and experience required to hold the party responsible for your injury accountable.

Last Updated: 02-08-2022
Last Updated: 02-08-2022
Written by: Michael A. Rose and Gregory Hach

Blood coagulant Eliquis is under attack in defective drug lawsuit

Posted on Tuesday, July 7th, 2015 at 2:50 pm    

A lawsuit has been filed in relation to Eliquis, a blood coagulant that allegedly contributed to the death of an individual due to bleeding, Market Watch reported on June 16.

The suit, which was filed in the Southern District of New York, claims that the defective drug is being promoted incorrectly as “one size fits all,” and it lacks a prominent warning that bleeding may be difficult to stop once it starts. Donald Herschell, 60, began taking the drug as prescribed by his doctor due to his atrial fibrillation. Subsequently, he developed gastrointestinal bleeding and succumbed to his condition in a hospital emergency room.

Eliquis, which acts as an anti-coagulant by stemming the bleeding and clotting in wounds, is distributed by two New York-based pharmaceutical giants, Pfizer Inc. and Bristol Myers Squibb.

Our attorneys at Hach & Rose, LLP, are knowledgeable and experienced when it comes to handling personal injury accident cases in New York such as those that include defective drugs, exposure to toxic substances, motor vehicular accidents, and more. If you are in need of legal advice or are looking for a lawyer to represent your personal injury case, call our offices today at (212) 779-0057 to begin taking action.

Our Office:

Hach & Rose, LLP, 112 Madison Ave,

10th Floor, New York, NY 10016

Conversion Pixel